|
|
More people become loyal Wobenzym users every day -- now discover how Wobenzym can enhance your quality of life! Jason Theodosakis, M.D. Maximizing the Arthritis Cure "The subject of some 25 years of research, much of it done in Germany, where it became known collectively as Wobenzym therapy, enzymes can foster healing in such problems as arthritis,immune insufficiency, pancreatitis and certain sports injuries." Dr. Robert C. Atkins, M.D. Dr. Atkins' Vita-Nutrient Solution "I recommend Wobenzym as a truly safe and effective pathway to support the body's natural repair of inflammatory joint conditions." Michael Loes, M.D., M.D.(H) Director of the Arizona Pain Institute Supports normal inflammation levels in case of sports injuries and arthritis. A dietary supplement to help your body's own natural repair processes. Wobenzym , a potent mix of purified, naturally occurring enzymes, has shown in numerous peer-reviewed studies to support normalization of inflammation and related pain. Proven safe and effective, and used by more than 100 million Europeans, Wobenzym is Germany's number 1 alternative to over-the-counter remedies such as aspirin. The beneficial effects of Wobenzym have been confirmed in hundreds of worldwide clinical studies. Wobenzym's standardized crystal enzyme matrix provides a superior synergistic effect to stimulate specific enzyme processes throughout the body in order to support normal inflammation levels. It's secret of effectiveness comes from its pure crystalline enzyme matrix which delivers superior proteolytic enzymatic conversion. This is why Wobenzym enzymes are measured in F.I.P. Units (Federation Internationale Pharmaceutique) the standard used by pharmaceutical companies worldwide to measure proteolytic enzyme activity. Furthermore, each Wobenzym tablet is protected with a clear enteric coating to assure proper utilization and specific biochemical reaction. Short-Term Treatment of Painful Osteoarthritis of the Knee with Oral Enzymes A Randomised, Double-Blind Study versus Diclofenac G. Klein1,2 and W. Kullich2 1 Rehabilitation Center for Rheumatic and Cardiovascular Diseases, Saalfelden, Austria 2 Ludwig Boltzmann Institute for Rehabilitation of Internal Diseases, Saalfelden, Austria Clin Drug Invest (2000): 19(1), 15-23. Abstract Objective: To compare the short-term efficacy and tolerability of an oral enzyme therapy with the NSAID diclofenac in patients with symptomatic osteoarthritis of the knee (gonarthritis). Methods: In a double-blind clinical trial, 73 patients with painful gonarthritis were randomised to receive 3 weeks of treatment with an oral enzyme preparation (Phlogenzym®) containing bromelain, trypsin and rutin (n = 36), or the NSAID diclofenac (n = 37). Efficacy was primarily evaluated using the Lequesne index (measuring pain and function of the affected knee). Other investigations included assessment of pain symptoms using a visual analogue scale (VAS), global assessment of efficacy and tolerability (by both patients and one physician), and various laboratory parameters. Patients were evaluated at baseline, at weekly intervals throughout the 3-week treatment period, and at 7 weeks (i.e. 4 weeks after discontinuing therapy). Results: The Lequesne index improved continuously in both groups: from 13.56 at baseline to 3.10 after 3 weeks (end of therapy) to 2.05 at 7 weeks (follow-up) in the enzyme group, and from 14.04 to 3.50 to 2.24, respectively, in the diclofenac group. Statistical evaluation showed the treatment groups to be equivalent; the lower bound of the 95% confidence interval of the Mann-Whitney estimator was above 0.44 (the limit for equivalence) at all time points. Global assessment of efficacy and tolerability of the drugs was 'very good' or 'good' for the majority patients. Conclusions: Short-term evaluation indicates that oral enzymes may be considered an effective and safe alternative to NSAIDs such as diclofenac in the treatment of painful gonarthritis. The effectiveness of systemic enzymotherapy in the complex treatment of rheumatoid arthritis Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V., Shemerovskaya T.G., Alekseeva T.G., Makulova T.G. Medical Academy of postgraduate education, Military Medical Academy, City rheumatological center, St. Petersburg, Russia. At present treatment of rheumatoid arthritis (RA) affecting main pathogenetic mechanisms of its development includes basic medications (crizanol, D-penicillinamine, methotrexate, chlorbutin etc.) as well as agents of "actual" therapy (NSAID and glucocorticoids) [1, 3-9,13, 14]. Frequent side effects of the medication of the first group and insufficient effectiveness of the second group demands the search for new therapeutic agents in the treatment of these patients [2, 4, 7, 9, 11, 14]. For this purpose we included medications of systemic enzymotherapy (Wobenzym and Phlogenzym) in the complex treatment of RA, which possess the properties of both basic medications and symptomatic antiinflammatory agents [10, 12, 15,16, 17]. The goal of the present investigation was to assess Wobenzym Conclusion The results of the performed study demonstrate new highly effective preparations with basic properties in the arsenal of antirheumatoid medications Wobenzym . Systemic enzymotherapy can be of RA treatment, which directly influences the pathogenetic mechanisms of the disease. The administration of the systemic enzymotherapy medications is advisable in combination with basic medications. Besides, Wobenzym a can be administered to RA patients in whom basic cytostatic therapy in contraindicated due to the presence of cytopenia, liver and kidney abnormality etc. Product 200 tablets - $49.00 These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
|
